-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
At present, the new crown vaccination campaign has been widely launched in China.
Since the new crown vaccine may be used in hundreds of millions of healthy people, its safety is an issue that cannot be ignored.
Yesterday, China’s core academic journal "Chinese Journal of Epidemiology" published a paper entitled "Safety Evaluation of Large-scale Emergency Use of Novel Coronavirus Inactivated Vaccine (Vero Cells)".
The new crown inactivated vaccine developed by the Wuhan Institute of Biological Products and Beijing Institute of Biological Products under Sinopharm China Biotechnology Co.
Two new inactivated vaccines developed by the Wuhan Institute of Biology and Beijing were approved to be included in the emergency use of China's new crown vaccine in June and July 2020.
The overall adverse reaction rate is low, and no serious adverse reactions have been found
The system monitored a total of 519,543 vaccination information and found 5164 pieces of adverse reaction information.
Adverse reactions of vaccination can generally be relieved within 3-4 days
Safety information shows that local reactions after vaccination mainly occur on the day of vaccination and within 24 hours after vaccination.
The lowest adverse reaction rate among the elderly over 60
Analyzing the incidence of adverse reactions according to population characteristics, it was found that the incidence of adverse reactions in women was 1.
According to age, the incidence of adverse reactions was the highest among people aged 12-18, reaching 11.
Some discussion
Some discussionDuring the discussion of the paper, the researchers pointed out that the safety data obtained during this emergency use process was significantly better than the safety results of the inactivated vaccine in the phase 2 clinical trial.
The types of adverse reactions found in this study are similar to those in clinical trials, and compared with other types of inactivated vaccines, the adverse reaction rate of the new coronavirus inactivated vaccine is also relatively low.
The author pointed out at the end of the paper that increasing the vaccination rate and gradually establishing herd immunity is one of the most effective ways to stop the spread of the new crown epidemic.